Arcellx (ACLX) Receivables (2022 - 2023)
Arcellx's quarterly Receivables came in at $36.9 million in Q3 2023, down 37.23% quarter-over-quarter from $58.8 million in Q2 2023.
Arcellx has reported Receivables for 2 years, with the latest figure at $36.9 million in Q3 2023.
- For the quarter ending Q3 2023, Receivables changed N/A year-over-year to $36.9 million; the trailing twelve-month figure through Sep 2023 stood at $36.9 million (changed N/A YoY), and the FY2022 full-year result was $2.0 million, changed N/A from the prior year.
- Receivables for Q3 2023 stood at $36.9 million, down from $58.8 million in the prior quarter.
- The five-year high for Receivables was $58.8 million in Q2 2023, with the low at $2.0 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 36.93 Mn |
| Jun 30, 2023 | 58.83 Mn |
| Mar 31, 2023 | 22.43 Mn |
| Dec 31, 2022 | 1.96 Mn |